India has the world’s second-largest COVID-19 outbreak. India desperately needs effective treatments. But the way the country’s drug regulator is handling potential therapies concerns many of us. The Drugs Controller General of India (DCGI) has approved several repurposed drugs for ‘restricted emergency use’ for treating the disease. On what basis were these drugs approved? Was …
Clinical trials
COVID-19: The need for evidence-based medicine
A number of old drugs approved for other diseases are being “repurposed” and tested for their safety and efficacy in COVID-19, in systematic clinical trials. They have emergency approval for use in COVID-19, but most are not yet proven for this use. Some drugs have received approval without adequate testing. Other drugs are being used …
Covid and Ayurveda
I criticised Patanjali Ayurveda’s claimed cure for COVID-19 for making unsubstantiated claims of efficacy. The drugs it is offering are untested and unproven. They haven’t proven their mettle in a well-conducted adequately sized randomized controlled trial. The proponents of Ayurveda, however, ask – can Ayurveda, or alternative medicine in general, be evaluated in the same …
Covid 19: We need well-designed clinical trials
On June 23, Patanjali Ayurved claimed that its preparations, ‘Coronil’ would cure COVID-19 in just a week. Scientists, researchers, physicians and media registered their strong protest and expressed robust disbelief for the outrageous and misleading ads. The company claimed that their medicine was tested in a randomised controlled trial (RCT) among COVID-19 positive patients and …
The many questions about Favipiravir
The Drugs Controller General of India (DCGI) has approved Glenmark Pharmaceuticals, an Indian pharmaceutical company, to sell generic versions of Favipiravir for the treatment of COVID-19. This drug, originally invented by a Japanese company, was meant to treat influenza. After the outbreak of COVID-19, doctors in China and Russia started using it to treat COVID-19 …